» Articles » PMID: 12917336

PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2003 Aug 15
PMID 12917336
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

PTEN is a tumor suppressor frequently inactivated in brain, prostate, and uterine cancers that acts as a phosphatase on phosphatidylinositol-3,4,5-trisphosphate, antagonizing the activity of the phosphatidylinositol 3'-OH kinase. PTEN manifests its tumor suppressor function in most tumor cells by inducing G(1)-phase cell cycle arrest. To study the mechanism of cell cycle arrest, we established a tetracycline-inducible expression system for PTEN in cell lines lacking this gene. Expression of wild-type PTEN but not of mutant forms unable to dephosphorylate phosphoinositides reduced the expression of cyclin D1. Cyclin D1 reduction was accompanied by a marked decrease in endogenous retinoblastoma (Rb) protein phosphorylation on cyclin D/CDK4-specific sites, showing an early negative effect of PTEN on Rb inactivation. PTEN expression also prevented cyclin D1 from localizing to the nucleus during the G(1)- to S-phase cell cycle transition. The PTEN-induced localization defect and the cell growth arrest could be rescued by the expression of a nucleus-persistent mutant form of cyclin D1, indicating that an important effect of PTEN is at the level of nuclear availability of cyclin D1. Constitutively active Akt/PKB kinase counteracted the effect of PTEN on cyclin D1 translocation. The data are consistent with an oncogenesis model in which a lack of PTEN fuels the cell cycle by increasing the nuclear availability of cyclin D1 through the Akt/PKB pathway.

Citing Articles

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.

Hu C, Chen Y, Yin X, Xu R, Yin C, Wang C Signal Transduct Target Ther. 2025; 10(1):39.

PMID: 39948335 PMC: 11825823. DOI: 10.1038/s41392-024-02098-3.


Metabolomics integrated genomics approach: Understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1/EGFR/PI3k/PTEN crosstalk.

Kadry M, Abd-Ellatef G, Ammar N, Hassan H, Hussein N, Kamel N Toxicol Rep. 2025; 14:101884.

PMID: 39886047 PMC: 11780168. DOI: 10.1016/j.toxrep.2024.101884.


Role of 3-mercaptopyruvate sulfurtransferase in cancer: Molecular mechanisms and therapeutic perspectives.

Zhang K, Zhu Y, Tang A, Zhou Z, Yang Y, Liu Z Transl Oncol. 2025; 52:102272.

PMID: 39813769 PMC: 11783123. DOI: 10.1016/j.tranon.2025.102272.


CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells.

Lim S, Lee S, Hong J, Lee J, Kim S Transl Cancer Res. 2024; 13(7):3695-3703.

PMID: 39145064 PMC: 11319972. DOI: 10.21037/tcr-24-20.


Translation into Clinical Practice of the G1-G7 Molecular Subgroup Classification of Glioblastoma: Comprehensive Demographic and Molecular Pathway Profiling.

Georgescu M Cancers (Basel). 2024; 16(2).

PMID: 38254850 PMC: 10814912. DOI: 10.3390/cancers16020361.


References
1.
Zhu X, Kwon C, Schlosshauer P, Ellenson L, Baker S . PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res. 2001; 61(11):4569-75. View

2.
Sherr C . The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000; 60(14):3689-95. View

3.
Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

4.
Baldin V, Lukas J, Marcote M, Pagano M, Draetta G . Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993; 7(5):812-21. DOI: 10.1101/gad.7.5.812. View

5.
Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A . Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem. 1995; 270(40):23589-97. DOI: 10.1074/jbc.270.40.23589. View